Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view
Open Access
Abstract
Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS—Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory and industry representatives. The evidence base for any specific criteria for the design and conduct of efficacy and safety antibiotic trials for children is very limited and will evolve over time as further studies are conducted. The suggestions being put forward here are based on the adult EMA guidance, adapted for neonates and children. In particular, this document provides suggested guidance on the general principles of harmonisation between regulatory and strategic trials, including (1) standardised key inclusion/exclusion criteria and widely applicable outcome measures for specific clinical infectious syndromes (CIS) to be used in CTs on efficacy of antibiotic in children; (2) key components of safety that should be reported in paediatric antibiotic CTs; (3) standardised sample sizes for safety studies. Summarising views from a range of key stakeholders, specific criteria for the design and conduct of efficacy and safety antibiotic trials in specific CIS for children have been suggested. The recommended criteria are intended to be applicable to both regulatory and clinical investigator-led strategic trials and could be the basis for harmonisation in the design and conduct of CTs on antibiotics in children. The next step is further discussion internationally with investigators, paediatric CTs networks and regulators.Keywords
This publication has 14 references indexed in Scilit:
- Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatmentCurrent Opinion in Infectious Diseases, 2017
- Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspectiveBMJ, 2016
- Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection researchThe Lancet Infectious Diseases, 2016
- Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic reviewThe Lancet Infectious Diseases, 2016
- The quality of safety reporting in trials is still suboptimal: Survey of major general medical journalsJournal of Clinical Epidemiology, 2011
- CONSORT 2010The Lancet, 2010
- Sample size calculation should be performed for design accuracy in diagnostic test studiesJournal of Clinical Epidemiology, 2005
- International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*Pediatric Critical Care Medicine, 2005
- If nothing goes wrong, is everything all right? Interpreting zero numerators.1983
- If Nothing Goes Wrong, Is Everything All Right?JAMA, 1983